RTP Mobile Logo
Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Waldenström Macroglobulinemia and Amyloidosis
Released January 2019

Proceedings from Part 2 of a 2-part satellite symposia series during the 60th ASH Annual Meeting. Featuring perspectives from Drs Rafael Fonseca, Sagar Lonial, Robert Z Orlowski, Noopur Raje and Professor Katja Weisel. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM), Waldenström macroglobulinemia (WM) and amyloidosis.

    OVERVIEW OF ACTIVITY
    Hematologic cancers include the lymphomas, the leukemias, MM and other related disorders stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that approximately 174,250 new lymphoid, myeloid and leukemic cancer cases will be identified in the United States in the year 2018, and 58,100 individuals will die from these diseases. Importantly, more than 70 drug products are currently labeled for use in the management of hematologic cancers with more than 120 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of their appropriate application across a vast spectrum of tumor types. This is particularly true within the realm of MM, WM and amyloidosis, where the past several years have yielded a staggering number of important clinical and research advances.

    These proceedings from a CME symposium during the ASH Annual Meeting use the perspectives of a group of community oncologists/hematologists gathered during a daylong working group to establish and subsequently address some of the most frequently encountered questions and controversies facing clinicians involved in the management of these diseases. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of MM, WM and amyloidosis with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Customize the use of induction, consolidation and maintenance therapeutic approaches for patients with MM in the post-transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
    • Consider published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapies in the nonresearch care of patients with relapsed/refractory (R/R) MM.
    • Appreciate the mechanisms of action of, supportive research database with and FDA-endorsed indications for monoclonal antibodies directed at CD38 and SLAMF7, and effectively identify where and how these agents should be integrated into the clinical management of newly diagnosed and R/R MM.
    • Design and implement a plan of care for patients with smoldering myeloma, considering the applicability of existing and emerging clinical trial data.
    • Develop an evidence-based algorithm for the use of stem cell transplant, chemotherapy and/or novel targeted agents in the management of primary amyloidosis.
    • Consider clinical and other patient-related factors in the sequence and selection of systemic therapy for patients with WM requiring active treatment.
    • Assess the ongoing clinical trials evaluating novel investigational approaches for MM, WM and amyloidosis, and obtain consent from appropriate patients for study participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASHMM2018/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Rafael Fonseca, MD
    Getz Family Professor of Cancer
    Chair, Department of Internal Medicine
    Mayo Clinic Arizona
    Scottsdale, Arizona

    Advisory Committee: AbbVie Inc, Aduro Biotech, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Juno Therapeutics, Kite Pharma Inc, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Takeda Oncology; Scientific Advisory Board: Adaptive Biotechnologies.

    Sagar Lonial, MD
    Professor and Executive Vice Chair
    Department of Hematology and Medical Oncology
    Chief Medical Officer
    Winship Cancer Institute
    Emory University
    Atlanta, Georgia

    Honoraria: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Merck, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.

    Robert Z Orlowski, MD, PhD
    Florence Maude Thomas Cancer Research Professor
    Chair Ad Interim, Department of Lymphoma and Myeloma
    Professor, Department of Experimental Therapeutics
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Kite Pharma Inc, Sanofi Genzyme; Contracted Research: Amgen Inc, BioTheryX Inc, Spectrum Pharmaceuticals Inc.

    Noopur Raje, MD
    Director, Center for Multiple Myeloma
    Massachusetts General Hospital Cancer Center
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Merck, Takeda Oncology.

    Professor Katja Weisel, MD
    Professor of Medicine
    Head of the Myeloma Center Tübingen
    Head of Oncological Outpatient Clinic
    Deputy Head of Clinical Trials
    University of Tübingen
    Tübingen, Germany

    Advisory Committee and Consulting Agreements: Adaptive Biotechnologies, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Takeda Oncology; Contracted Research: Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Sanofi Genzyme; Data and Safety Monitoring Board: Amgen Inc, Celgene Corporation, Karyopharm Therapeutics, Oncopeptides.

    CONSULTING ONCOLOGISTS/HEMATOLOGISTS — The following consulting oncologists/hematologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Amy Bessnow, MD, MPH
    Seacoast Cancer Center
    Wentworth-Douglass Hospital
    Dover, New Hampshire

    No relevant conflicts of interest to disclose.

    Suzanne Cole, MD
    Medical Director
    University Hospital Simmons Cancer Clinic, Richardson-Plano
    Assistant Professor, Division of Hematology and Oncology
    UT Southwestern Medical Center
    Dallas, Texas

    No relevant conflicts of interest to disclose.

    Jewel Johl, MD
    Diablo Valley Oncology and Hematology Medical Group
    Pleasant Hill, California

    No relevant conflicts of interest to disclose.

    Kapisthalam S Kumar, MD
    Florida Cancer Specialists
    New Port Richey, Florida

    No relevant conflicts of interest to disclose.

    Erik Rupard, MD
    Chief, Hematology-Oncology
    McGlinn Cancer Institute
    The Reading Hospital
    West Reading, Pennsylvania

    No relevant conflicts of interest to disclose.

    Rajni Sinha, MD
    Piedmont Cancer Institute
    Atlanta, Georgia

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: January 2019
    Expiration date: January 2020

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Introduction

Up-Front Management of Multiple Myeloma (MM)

Consolidation and Maintenance Therapy

Management of Relapsed/Refractory MM

Novel Strategies Under Investigation for the Treatment of MM

Smoldering Myeloma, Amyloidosis and Waldenström Macroglobulinemia

Select Publications